Increased risk of borderline ovarian tumors in women with a history of pelvic inflammatory disease: A nationwide population-based cohort study

Gynecologic Oncology

Volumn 143, Issue 2, 2016, Pages 346-351

  Rasmussen, Christina B ^a   Jensen, Allan ^a   Albieri, Vanna ^a   Andersen, Klaus K ^a   Kjaer, Susanne K ^a,b  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Borderline ovarian tumor; Cohort study; Inflammation; Pelvic inflammatory disease; Risk factor

Indexed keywords

ADULT; ARTICLE; BORDERLINE OVARIAN TUMOR; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DANISH CITIZEN; DENMARK; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; OVARY TUMOR; PELVIC INFLAMMATORY DISEASE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; UTERINE TUBE LIGATION; COMPLICATION; MIDDLE AGED; OVARIAN NEOPLASMS; RISK;

ADULT; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PELVIC INFLAMMATORY DISEASE; RISK;

EID: 84995380054     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.08.318     Document Type: Article

References (34)

1. [1] Hannibal, C.G., Huusom, L.D., Kjaerbye-Thygesen, A., et al. Trends in incidence of borderline ovarian tumors in Denmark 1978–2006. Acta Obstet. Gynecol. Scand. 90:4 (2011), 305–312.
2. [2] Hart, W.R., Borderline epithelial tumors of the ovary. Mod. Pathol. 18:Suppl. 2 (2005), S33–S50.
3. [3] Crispens, M.A., Borderline ovarian tumours: a review of the recent literature. Curr. Opin. Obstet. Gynecol. 15:1 (2003), 39–43.
4. [4] Morris, C.R., Liu, L., Rodriguez, A.O., et al. Epidemiologic features of borderline ovarian tumors in California: a population-based study. Cancer Causes Control 24:4 (2013), 665–674.
5. [5] FIGO, Classification and staging of malignant tumours in the female pelvis. Acta Obstet. Gynecol. Scand. 50:1 (1971), 1–7.
6. [6] Harris, R., Whittemore, A.S., Itnyre, J., Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative ovarian cancer group. Am. J. Epidemiol. 136:10 (1992), 1204–1211.
7. [7] Huusom, L.D., Frederiksen, K., Hogdall, E.V., et al. Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: a Danish case-control study. Cancer Causes Control 17:6 (2006), 821–829.
8. [8] Modugno, F., Ness, R.B., Wheeler, J.E., Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness. Ann. Epidemiol. 11:8 (2001), 568–574.
9. [9] Ness, R.B., Cottreau, C., Possible role of ovarian epithelial inflammation in ovarian cancer. J. Natl. Cancer Inst. 91:17 (1999), 1459–1467.
10. [10] Brunham, R.C., Gottlieb, S.L., Paavonen, J., Pelvic inflammatory disease. N. Engl. J. Med. 372:21 (2015), 2039–2048.
11. [11] Lin, H.W., Tu, Y.Y., Lin, S.Y., et al. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol. 12:9 (2011), 900–904.
12. [12] McAlpine, J.N., Lisonkova, S., Joseph, K.S., et al. Pelvic inflammation and the pathogenesis of ovarian cancer: a cohort study. Int. J. Gynecol. Cancer 24:8 (2014), 1406–1413.
13. [13] Merritt, M.A., Green, A.C., Nagle, C.M., et al. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int. J. Cancer 122:1 (2008), 170–176.
14. [14] Ness, R.B., Grisso, J.A., Cottreau, C., et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 11:2 (2000), 111–117.
15. [15] Parazzini, F., La Vecchia, C., Negri, E., et al. Pelvic inflammatory disease and risk of ovarian cancer. Cancer Epidemiol. Biomark. Prev. 5:8 (1996), 667–669.
16. [16] Rasmussen, C.B., Faber, M.T., Jensen, A., et al. Pelvic inflammatory disease and risk of invasive ovarian cancer and ovarian borderline tumors. Cancer Causes Control 24:7 (2013), 1459–1464.
17. [17] Risch, H.A., Howe, G.R., Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol. Biomark. Prev. 4:5 (1995), 447–451.
18. [18] Shu, X.O., Brinton, L.A., Gao, Y.T., et al. Population-based case-control study of ovarian cancer in shanghai. Cancer Res. 49:13 (1989), 3670–3674.
19. [19] Wu, A.H., Pearce, C.L., Tseng, C.C., et al. Markers of inflammation and risk of ovarian cancer in Los Angeles County. Int. J. Cancer 124:6 (2009), 1409–1415.
20. [20] Rasmussen, C.B., Kjaer, S.K., Albieri, V., et al. Pelvic inflammatory disease and risk of ovarian cancer and borderline ovarian tumors: a pooled analysis of 13 case-control studies. Am. J. Epidemiol., 2016 (In press).
21. [21] Pedersen, C.B., The Danish civil registration system. Scand. J. Public Health 39:7 Suppl. (2011), 22–25.
22. [22] Lynge, E., Sandegaard, J.L., Rebolj, M., The Danish National Patient Register. Scand. J. Public Health 39:7 Suppl. (2011), 30–33.
23. [23] Bjerregaard, B., Larsen, O.B., The Danish Pathology Register. Scand. J. Public Health 39:7 Suppl. (2011), 72–74.
24. [24] Gjerstorff, M.L., The Danish Cancer Registry. Scand. J. Public Health. 39:7 Suppl. (2011), 42–45.
25. [25] Osterlind, A., Jensen, O.M., Evaluation of cancer registration in Denmark in 1977. Preliminary evaluation of cancer registration by the Cancer Register and the National Patient Register. Ugeskr. Laeger 147:31 (1985), 2483–2488.
26. [26] Blenstrup, L.T., Knudsen, L.B., Danish registers on aspects of reproduction. Scand. J. Public Health. 39:7 Suppl. (2011), 79–82.
27. [27] Kildemoes, H.W., Sorensen, H.T., Hallas, J., The Danish National Prescription Registry. Scand. J. Public Health. 39:7 Suppl. (2011), 38–41.
28. [28] R Core Team, R: a Language and Environment for Statistical Computing. 2013, R Foundation for Statistical Computing, Vienna, Austria (Available from: http://www.R-project.org/).
29. [29] Risch, H.A., Marrett, L.D., Jain, M., et al. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am. J. Epidemiol. 144:4 (1996), 363–372.
30. [30] Vang, R., Shih, I., Kurman, R.J., Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology 62:1 (2013), 44–58.
31. [31] Kurman, R.J., Vang, R., Junge, J., et al. Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am. J. Surg. Pathol. 35:11 (2011), 1605–1614.
32. [32] Seidman, J.D., Sherman, M.E., Bell, K.A., et al. Salpingitis, salpingoliths, and serous tumors of the ovaries: is there a connection?. Int. J. Gynecol. Pathol. 21:2 (2002), 101–107.
33. [33] Kurman, R.J., Shih, I., Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. Hum. Pathol. 42:7 (2011), 918–931.
34. [34] Hillis, S.D., Joesoef, R., Marchbanks, P.A., et al. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility. Am. J. Obstet. Gynecol. 168:5 (1993), 1503–1509.